A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Phase 3
450
about 2.1 years
18–74
35 sites in AL, AR, CA +15
About this study
Researchers are testing a treatment called azetukalner versus a placebo for people with major depressive disorder. The trial will last about 753 days and involve around 450 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Azetukalner
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Change from baseline in the Hamilton Depression Rating Scale, 17-item (HAMD-17) score at Week 6
Secondary: Change from baseline in the Clinical Global Impression of Severity (CGI-S) score at Week 6, Change from baseline in the Hamilton Depression Rating Scale, 17-item (HAMD-17) score at Week 1, Change from baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) score at Week 6, To assess the safety and tolerability of azetukalner (e.g., adverse events)
Psychiatry / Mental Health